ArticleJournal of virology1998
Neutralizing monoclonal antibodies block human immunodeficiency virus type 1 infection of dendritic cells and transmission to T cells.
Article in Journal of virology, 1998. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 34 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
34 citing papers in PubMed, 85 citations in OpenAlex.
- Engineered CD4 T cells expressing a membrane anchored viral inhibitor restrict HIV-1 throughFrontiers in immunology · 2023Article
- Absence of antibody responses to SARS-CoV-2 N protein in COVID-19 vaccine breakthrough cases.Experimental biology and medicine (Maywood, N.J.) · 2022Article
- Virus-Mediated Cell-Cell Fusion.International journal of molecular sciences · 2020Review
- HIV-1 cell-to-cell transmission and broadly neutralizing antibodies.Retrovirology · 2018Review
- The Glycosylphosphatidylinositol-Anchored Variable Region of Llama Heavy Chain-Only Antibody JM4 Efficiently Blocks both Cell-Free and T Cell-T Cell Transmission of Human Immunodeficiency Virus Type 1.Journal of virology · 2016Article
- Early short-term treatment with neutralizing human monoclonal antibodies halts SHIV infection in infant macaques.Nature medicine · 2016Article
- Modeling mucosal cell-associated HIV type 1 transmission in vitro.The Journal of infectious diseases · 2014Review
- Which Antibody Functions are Important for an HIV Vaccine?Frontiers in immunology · 2014Review
- Closing the door to human immunodeficiency virus.Protein & cell · 2013Review
- Review
- Transmembrane domain membrane proximal external region but not surface unit-directed broadly neutralizing HIV-1 antibodies can restrict dendritic cell-mediated HIV-1 trans-infection.The Journal of infectious diseases · 2012Article
- Attachment and fusion inhibitors potently prevent dendritic cell-driven HIV infection.Journal of acquired immune deficiency syndromes (1999) · 2011Article
- Stimulation of HIV-1 replication in immature dendritic cells in contact with primary CD4 T or B lymphocytes.Journal of virology · 2010Article
- Antibody-Mediated Fcγ Receptor-Based Mechanisms of HIV Inhibition: Recent Findings and New Vaccination Strategies.Viruses · 2009Article
- Glycosphingolipid composition of human immunodeficiency virus type 1 (HIV-1) particles is a crucial determinant for dendritic cell-mediated HIV-1 trans-infection.Journal of virology · 2009Article
- Article
- Article
- Infection of specific dendritic cells by CCR5-tropic human immunodeficiency virus type 1 promotes cell-mediated transmission of virus resistant to broadly neutralizing antibodies.Journal of virology · 2004Article
- Effects of antibody on viral kinetics in simian/human immunodeficiency virus infection: implications for vaccination.Journal of virology · 2004Article
- Transfer of neutralizing IgG to macaques 6 h but not 24 h after SHIV infection confers sterilizing protection: implications for HIV-1 vaccine development.Proceedings of the National Academy of Sciences of the United States of America · 2003Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
15 authors at 4 institutions in 1 country.
Funding
Abstract
Prevention of the initial infection of mucosal dendritic cells (DC) and interruption of the subsequent transmission of HIV-1 from DC to T cells are likely to be important attributes of an effective human immunodeficiency virus type 1 (HIV-1) vaccine. While anti-HIV-1 neutralizing antibodies have been difficult to elicit by immunization, there are several human monoclonal antibodies (MAbs) that effectively neutralize virus infection of activated T cells. We investigated the ability of three well-characterized neutralizing MAbs (IgG1b12, 2F5, and 2G12) to block HIV-1 infection of human DC. DC were generated from CD14(+) blood cells or obtained from cadaveric human skin. The MAbs prevented viral entry into purified DC and the ensuing productive infection in DC/T-cell cultures. When DC were first pulsed with HIV-1, MAbs blocked the subsequent transmission to unstimulated CD3(+) T cells. Thus, neutralizing antibodies can block HIV-1 infection of DC and the cell-to-cell transmission of virus from infected DC to T cells. These data suggest that neutralizing antibodies could interrupt the initial events associated with mucosal transmission and regional spread of HIV-1.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.